FutureGen Biopharmaceutical (Beijing) Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2018-01-23
- Employees
- 51
- Market Cap
- -
- Website
- http://www.futuregen.com.cn
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Phase 3
Recruiting
- Conditions
- Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
- Target Recruit Count
- 486
- Registration Number
- NCT06177041
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
Phase 1
Recruiting
- Conditions
- Advanced Unresectable Solid Tumors
- Interventions
- Drug: M108
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
- Target Recruit Count
- 152
- Registration Number
- NCT04894825
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath